Theratechnologies Agrees To Be Taken Private By CB Biotechnology In $254 Mln Deal

Theratechnologies Inc. (THTX) has agreed to be taken private by CB Biotechnology, an affiliate of Future Pak, LLC, for US$3.01 cash per share plus one contingent value right (CVR) potentially worth up to US$1.19, valuing the transaction at US$254 million assuming full CVR payout. This offer represents significant premiums of 126% (cash) and 216% (cash plus CVR) over the company's Nasdaq closing price on April 10, 2025, and 90% and 165% over the 30-day volume-weighted average price, providing a compelling exit for shareholders. Upon completion, Theratechnologies will become a privately held company, delisting from the Toronto Stock Exchange and Nasdaq.

Analysis

Theratechnologies Inc. has entered into a definitive agreement to be acquired and taken private by CB Biotechnology, an affiliate of Future Pak, LLC. The deal structure offers shareholders US$3.01 in cash per share plus a Contingent Value Right (CVR) with a potential additional payout of up to US$1.19, contingent on undisclosed milestones. The total transaction is valued at up to US$254 million, assuming the CVR is fully realized. This offer presents a substantial premium to shareholders, with the cash component alone representing a 126% premium over the closing price on April 10, 2025, and the total potential consideration representing a 216% premium. Deal certainty is supported by Future Pak's secured financing, which includes a US$220 million debt commitment letter. Standard deal protection measures are in place, including non-solicitation covenants, a US$6 million termination fee payable by Theratechnologies, and a US$12 million reverse termination fee payable by the acquirer, which provides a degree of protection against non-completion. Upon closing, Theratechnologies will be delisted from the TSX and Nasdaq, providing a definitive liquidity event for current public investors.

Key Decisions for Investors

• For existing shareholders, this transaction provides a compelling liquidity event at a significant premium to recent trading levels; the primary consideration is whether to hold through closing to capture the full cash and potential CVR value.
• Investors engaging in merger arbitrage should focus on the spread between the current trading price and the US$3.01 cash offer, while carefully assessing the probability of the CVR milestones being met to value the transaction's full potential return.
• The likelihood of a superior competing offer emerging is tempered by the inclusion of a non-solicitation clause and a US$6 million termination fee, suggesting that the current deal with Future Pak is the most probable outcome for investors to model.